CFG-920
- Generic Name
- CFG-920
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 33
- Registration Number
- NCT03843918
- Locations
- 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China
🇨🇳ZheJiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01647789
- Locations
- 🇺🇸
UCSF Medical Center Dept of Oncology, San Francisco, California, United States
🇺🇸Cancer Therapy & Research Center UT Health Science Center InstituteForDrugDevelopment(2), San Antonio, Texas, United States
🇺🇸Seattle Cancer Care Alliance Dept. of SCCA, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath